NCT04768270 is a clinical trial of no intervention in Ovarian Cancer, sponsored by Chongqing University Cancer Hospital.

Who is sponsoring NCT04768270?

NCT04768270 is sponsored by Chongqing University Cancer Hospital.

What drugs are being tested in NCT04768270?

Interventions in NCT04768270: no intervention.

What condition does NCT04768270 study?

NCT04768270 studies Ovarian Cancer.

Is NCT04768270 still recruiting?

NCT04768270 is currently status unknown. Last updated 31 August 2023.

Last reviewed 2023-08-31 · How we verify

NCT04768270

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Culture of Ovarian Cancer Organoids and Drug Screening

Status unknown Last updated 31 August 2023

What this trial tests

trial testing no intervention in Ovarian Cancer in 30 participants. Status unknown.

Timeline

12 April 2022

Primary endpoint
31 December 2023

31 December 2024

Quick facts

Lead sponsor	Chongqing University Cancer Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	30
Start date	12 April 2022
Primary completion	31 December 2023
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

no intervention

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Chongqing University Cancer Hospital

Who can join

Adults 18 to 70, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The tumor organoids platform can provide the precise genetic information and phenotype, as well as the heterogeneity of the tumor, thus provide information on drug sensitivity specific to the patient.This is an exploratory research to see if organoids testing could help guide precision treatment for ovarian cancer(OC) patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.
Letai A, Bhola P, Welm AL. · · 2022 · cited 182× · PMID 34951956 · DOI 10.1016/j.ccell.2021.12.004
Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.
Zhou Z, Cong L, Cong X. · · 2021 · cited 112× · PMID 35036354 · DOI 10.3389/fonc.2021.762184
Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
Thorel L, Perréard M, Florent R, Divoux J, et al · · 2024 · cited 90× · PMID 38945959 · DOI 10.1038/s12276-024-01272-5
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
Nero C, Vizzielli G, Lorusso D, Cesari E, et al · · 2021 · cited 42× · PMID 33789687 · DOI 10.1186/s13046-021-01917-7
Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.
Ciucci A, Buttarelli M, Fagotti A, Scambia G, et al · · 2022 · cited 32× · PMID 35705879 · DOI 10.1007/s00018-022-04395-y
Reconstructing the tumor architecture into organoids.
Luo Z, Zhou X, Mandal K, He N, et al · · 2021 · cited 32× · PMID 34153370 · DOI 10.1016/j.addr.2021.113839
Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07253506 — Turkish Adaptation, Validity, and Reliability Study of the Patient Experience With Treatment and Self-Management Scale i · not yet recruiting
NCT07253519 — The Relationship Between Mood and Insomnia Severity and Caregiver Burden in Caregivers of Stroke · not yet recruiting
NCT07194096 — Stress Hyperglycemia Ratio and Postoperative Delirium · not yet recruiting
NCT07240337 — Botulinum Toxin Applications in Hemiplegic Patients · recruiting

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Chongqing University Cancer Hospital trials

Trials by the same sponsor.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07425795 — Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of E · Phase 2 · recruiting
NCT07248696 — Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Pro · NA · active not recruiting
NCT07248670 — Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC · Phase 3 · active not recruiting
NCT06981858 — A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advan · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04768270 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chongqing University Cancer Hospital
Last refreshed: 31 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04768270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing